Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CATCO: Canadian Treatments for COVID-19
NCT04330690Phase 3Unknown
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Mar 2020
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of artesunate, imatinib, infliximab, dexamethasone, LSALT peptide in coronavirus disease 2019 (COVID-19), sponsored by Sunnybrook Health Sciences Centre. Status: unknown.
02
Drugs
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04330690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04330690.